ApprovedFDA approval

Lyrfigtu (lirafugratinib)

Elevar Therapeutics

Marketer take

Limited to previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma, so molecular testing rates and reach into GI oncology centers define the market, and existing FGFR inhibitor brands face a direct rival.

Sponsor company
Elevar Therapeutics
Indication
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
Therapeutic area
Oncology
Event
FDA approval
Date
Sep 23, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move